HomeNewsBusinessSchengen visa issues saw Indian travellers turn to SE Asia, West Asia in April-June

Schengen visa issues saw Indian travellers turn to SE Asia, West Asia in April-June

However, with the end of the summer vacation cycle in India, and more international routes opening up post-COVID restrictions, demand is expected to taper back and spread out across other countries.

July 15, 2022 / 18:43 IST
Story continues below Advertisement
Representative image
Representative image

As COVID-19-related international border restrictions gradually eased in the quarter ending June 2022, Indian travellers looked to South East Asian countries due to increased visa processing time for Schengen visas.

Visa processing time for some nations in Europe and the United Kingdom has risen to four to 10 weeks now, which has forced many would-be travellers to cancel flights and bookings.

Story continues below Advertisement

"There has been a massive spike in demand for visas. We’re experiencing unprecedented volumes — between 20,000 to 23,000 visa applications daily on an average from India, given the pent-up travel demand," VFS Global COO (South Asia) Prabuddha Sen said .

However, countries including Thailand, Indonesia, Malaysia, Singapore, and the Maldives have emerged as the biggest beneficiaries of delays in processing Schengen visas, travel agents and visa processing firms said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show